

Thermo Fisher launches TaqPath COVID-19 2.0 test

written by CAP TODAY
June 24, 2021

June 24, 2021—Thermo Fisher Scientific launched its CE-IVD-marked TaqPath COVID-19 Fast PCR Combo Kit 2.0.



©2026 CAP TODAY, all rights reserved.

Implementing HHS reporting requirements of COVID-19 test results and future epidemics: a call to IVD companies for immediate action

written by CAP TODAY
June 24, 2021

In response to the rapidly evolving COVID-19 crisis, the Department of Health and Human Services (HHS) issued a laboratory data reporting guidance for COVID-19 testing on June 4, 2020 to assure the timely and quality data reporting to state and federal public health agencies of SARS-CoV-2 diagnostic test results, using LOINC and SNOMED-CT in electronic reporting systems.



©2026 CAP TODAY, all rights reserved.

Biocept, Quest to provide testing for lung cancer patients

written by CAP TODAY
June 24, 2021

June 23, 2021—Biocept announced a collaboration with Quest Diagnostics to provide laboratory testing services to Quest patients for its Target Selector NGS-based liquid biopsy targeted lung cancer panel.



©2026 CAP TODAY, all rights reserved.

Epredia, Aiforia to distribute AI-based pathology software

written by CAP TODAY
June 24, 2021

June 22, 2021—Epredia and Aiforia announced they have entered into a commercial distribution agreement for Aiforia's portfolio of preclinical and clinical pathology tools.



©2026 CAP TODAY, all rights reserved.

[FDA authorizes BD COVID-19, flu rapid antigen test](#)

written by CAP TODAY
June 24, 2021

BD announced that the FDA granted emergency use authorization for its rapid antigen test that can detect SARS-CoV-2, influenza A, and influenza B in a single test. The BD Veritor System for Rapid Detection of SARS-CoV-2 & Flu A+B assay takes about 15 minutes to run on the BD Veritor Plus system and distinguishes between SARS-CoV-2, influenza A, and influenza B by providing definitive positive or negative individual digital display readouts for all three. BD plans to launch the test this summer for the 2021-2022 flu season. The test is intended for individuals who are suspected by a health care provider of having COVID-19, flu A, or flu B within six days of symptom onset.



©2026 CAP TODAY, all rights reserved.

[Bio-Plex IgG SARS-CoV-2 serology assays](#)

written by CAP TODAY
June 24, 2021

June 2021—Bio-Rad Laboratories launched the Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel, a qualitative multiplex immunoassay kit that detects IgG antibodies against four SARS-CoV-2 antigens in less than three hours.



©2026 CAP TODAY, all rights reserved.

[OptraScan unveils OS-Ultra 320](#)

written by CAP TODAY
June 24, 2021

June 2021—OptraScan launched the OS-Ultra 320 high-speed digital pathology scanner. The OS-Ultra 320 scans a 15- × 15-mm region at 40 × magnification in less than 60 seconds and features no-touch, continuous loading operation. The scanner uses real-time autofocus and offers a resolution of 0.25 μm/pixel. It accepts 25- × 75-mm and 50- × 75-mm slides with slide tolerances of ± 1 mm long, ± 1 mm wide, and ± 0.2 mm thick.



©2026 CAP TODAY, all rights reserved.

[Roche to acquire GenMark Diagnostics](#)

written by CAP TODAY
June 24, 2021

June 2021—Roche and GenMark Diagnostics have entered into a definitive merger agreement for Roche to acquire GenMark for about \$1.8 billion on a fully diluted basis. GenMark's syndromic panel testing portfolio will complement Roche's molecular diagnostics portfolio, and Roche's global network will enable expanded reach for GenMark's products.



©2026 CAP TODAY, all rights reserved.

[CellBlockistry 101](#)

written by CAP TODAY
June 24, 2021

June 2021—*CellBlockistry 101—The Textbook of Cell-Blocking Science* addresses the cell-block-making process and cell-blocking-related challenges with advances in improved interdisciplinary coordination for optimal outcome and ongoing research in the field. The book is intended for pathologists, cytopathologists, cytotechnologists, cytoprep technologists, and others in fields associated with cell blocks directly or indirectly, including histotechnologists and radiologists.



©2026 CAP TODAY, all rights reserved.

[PerkinElmer launches solutions to detect SARS-CoV-2 variants](#)

written by CAP TODAY
June 24, 2021

June 2021—PerkinElmer launched two research use only solutions, PKamp VariantDetect SARS-CoV-2 RT-PCR Assay and the next-generation-sequencing-based Nextflex Variant-Seq SARS-CoV-2 Kit. The PKamp VariantDetect SARS-CoV-2 RT-PCR assay can detect mutations associated with B.1.1.7, B.1.351, and P.1 variants. The Nextflex Variant-Seq SARS-CoV-2 WGS workflow can detect all SARS-CoV-2 genetic changes relative to the strain originally identified in Wuhan, China.



©2026 CAP TODAY, all rights reserved.